Table 2.
PE | E | ΔE | PI | I | ΔI | ΔT | |
---|---|---|---|---|---|---|---|
MR day 1 | |||||||
Glucose (mmol/L) | 8.7 ± 0.5 | 7.6 ± 0.3 | −1.1 ± 0.2** | 8.7 ± 0.5 | 7.6 ± 0.3 | −1.1 ± 0.4* | −0.0 ± 0.3 |
FAs (mmol/L) | 0.55 ± 0.03 | 0.60 ± 0.03 | 0.05 ± 0.04 | 0.56 ± 0.04 | 0.50 ± 0.05 | −0.06 ± 0.05 | 0.10 ± 0.04* |
β-OH butyrate (mmol/L) | 0.25 ± 0.02 | 0.29 ± 0.03 | 0.05 ± 0.02* | 0.26 ± 0.02 | 0.24 ± 0.02 | −0.02 ± 0.01†† | 0.05 ± 0.02 * |
Insulin (pmol/L) | 127 ± 17 | 103 ± 14 | −24 ± 11 | 127 ± 17 | 141 ± 16 | 14 ± 10† | −38 ± 12** |
Respiratory quotient | 0.80 ± 0.01 | 0.75 ± 0.03 | −0.04 ± 0.04 | 0.84 ± 0.02 | 0.84 ± 0.02 | 0.00 ± 0.02 | −0.09 ± 0.03* |
MR day 2—acipimox | |||||||
Glucose (mmol/L) | 8.7 ± 0.5 | 7.6 ± 0.3 | −1.1 ± 0.4** | 8.1 ± 0.3 | 7.6 ± 0.3 | −0.6 ± 0.2* | −0.1 ± 0.2 |
FAs (mmol/L) | 0.33 ± 0.04‡‡ | 0.41 ± 0.04‡‡ | 0.08 ± 0.05 | 0.34 ± 0.03‡‡ | 0.32 ± 0.04‡‡ | −0.02 ± 0.04 | 0.10 ± 0.05 |
Ketone bodies (umol/L) | 0.23 ± 0.01 | 0.25 ± 0.02 | 0.02 ± 0.01 | 0.23 ± 0.02‡ | 0.22 ± 0.02‡ | −0.01 ± 0.02 | 0.04 ± 0.02* |
Insulin (pmol/L) | 139 ± 24 | 87 ± 9 | −52 ± 19* | 106 ± 13 | 149 ± 23 | 43 ± 14**†† | −62 ± 17** |
Data are presented as Mean ± SEM
PE Pre-Empagliflozin, E Empagliflozin, PI Pre-Insulin, I Insulin, ΔE E-PE, ΔI I-PI, ΔT E-I
*p < 0.05; **p < 0.01; †p < 0.05; ††p < 0.01 vs ΔE. ‡p < 0.05 vs MR Day 1. ‡‡p < 0.01 vs MR Day 1